FDA proposal on GLP-1 503B compounding and Q1 earnings preview
The FDA has proposed removing the three main GLP-1 molecules from the 503B compounding list, and the market reaction has overstated the hit to HIMS. HIMS mainly operates through the 503A route and has already completed its strategic shift to branded drugs, so its actual reliance on 503B is minimal. A clear-out of competitors may even work in its favour.
Competitive impact
- HIMS angle
Has locked in branded-drug partnerships with Novo and Lilly and may benefit from rivals being cleared out
- Seeking Alpha view
A Seeking Alpha analysis of 1 May argues the rule may actually help HIMS, as the competitive landscape concentrates in leading platforms with established brand partnerships
- True victims
Small telehealth companies that rely on 503B outsourcing facilities for large-scale compounding
FDA 503B proposal
- Action
The FDA has formally proposed removing semaglutide, tirzepatide and liraglutide from the 503B bulk compounding list
- Date
30 Apr 2026
- Final decision
After the public comment period ends
- Public comment deadline
29 Jun 2026
- Reason
There is no clinical need for outsourcing facilities to compound these drugs in bulk
Key insights
- 503B is the large-scale bulk production route for outsourcing facilities (no individual prescription needed)
- 503A is the individualised compounding route for licensed doctors and pharmacists (individual prescription needed, regulated state by state)
- HIMS mainly uses the 503A route, not 503B
- A researcher at the consultancy Avalere Health said explicitly that the 503B list exclusion may not affect how current GLP-1 compounded drugs actually operate (quoted by NBC News)
- HIMS has already completed its strategic shift from compounded drugs to distributing branded drugs (the Novo and Lilly partnerships are both in place), so its reliance on 503B is minimal
Price action
- Price
$27.39 (close on 2 May 2026)
- Pullback
About 12% below the $31 high
Q1 earnings preview
- Date
11 May 2026, after the close
- EPS consensus
$0.06 (down 70% year on year)
- Revenue consensus
$621 million (up 6% year on year)
Sources (1)
- NBC News, Seeking Alpha (1 May 2026), FDA official proposal notice (30 Apr 2026)
A brief is a lead for our research, not a verified conclusion or advice.